VE-2851: A Comprehensive Profile of a Novel Precision Oral Anticoagulant with a Differentiated Safety Profile

Executive Summary

VE-2851 is an orally available, direct thrombin inhibitor under development by Verseon Corporation for the prevention of strokes and heart attacks. It belongs to a novel drug class known as Precision Oral Anticoagulants (PROACs), which are being engineered to fundamentally address the primary limitation of existing antithrombotic therapies: the inherent risk of major bleeding. Currently designated as being in the "Clinical" stage of development, VE-2851 represents a second-generation candidate from Verseon's proprietary, computationally driven drug discovery platform.

The core value proposition of VE-2851 lies in its unique and highly differentiated mechanism of action. While it effectively inhibits thrombin to prevent the formation of fibrin-based blood clots, it has been specifically designed to spare thrombin's role in mediating platelet activation. This selective activity is hypothesized to uncouple antithrombotic efficacy from bleeding risk by preserving primary hemostasis, the body's initial response to vascular injury. This profile is supported by compelling preclinical data, which demonstrates that VE-2851 provides potent anticoagulation in animal models of thrombosis while exhibiting a dramatically improved safety profile. Notably, in rodent models, VE-2851 was associated with over 15 times less blood loss compared to apixaban, a market-leading direct oral anticoagulant (DOAC).